Benda Pharmaceutical Reports Fourth Quarter and Full Year 2007 Financi...(tests in October 2007. However be...),Health

2007. However, before resuming operations, Yidu Benda must conduct

further testing with relevant government authorities and, at this time,

management cannot estimate the exact timing of the process.

-- Jiangling Benda plant update: The upgrade process of Jiangling Benda

has been completed and is now waiting for a GMP Certificate from

China's State Food and Drug Administration (SFDA). However, due to the

overhaul and restructuring of the SFDA, Benda management cannot

estimate the exact timing for obtaining a GMP certificate.

-- Intellectual property: SiBiono, a subsidiary of Benda Pharmaceutical,

recently entrusted Grandall Legal Group Shenzhen Law Firm to issue a

legal letter to Zhaohui Peng, one of the shareholders of SiBiono and

the inventor of Gendicine, to request that Peng transfer all existing

title of patents to SiBiono. SiBiono has received two of the six

outstanding patents, and is currently in negotiations with Peng

regarding the remaining patent transfers.

Financial Guidance

While the Company remains confident in its ability to pursue opportunities in China's healthcare market, the Company is withdrawing any previously stated financial projections at this time. The Company is diligently working to meet the previously announced terms of its March 2007 financing, which included receiving effective status for its registration statement.

The Company's operating priorities include the roll out of Gendicine to new hospitals and clinics in 2008. These operating priorities also include ultimately utilizing additional capacity at Jiangling Benda and Yidu Benda, although these facilities require either GMP approval or re-examination by government authorities, the time frame of which relies entirely on the relevant government authorities and not on Benda Pharmaceutical.

About Benda Pharmaceut
'/>"/>